NCT03770234View on ClinicalTrials.gov

Clinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 Hours

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 5, 2004

Primary Completion Date

May 26, 2004

Study Completion Date

May 26, 2004

Conditions
PainPharmacokinetics
Interventions
DRUG

Transtec 35 µg/hour transdermal patch

Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.

Trial Locations (1)

67269

Institut für Klinische Pharmakologie Bobenheim, Grünstadt

Sponsors

Lead Sponsor

Grünenthal GmbH
All Listed Sponsors
lead

Grünenthal GmbH

INDUSTRY

NCT03770234 - Clinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 Hours | Biotech Hunter | Biotech Hunter